| |
| |
|
| Insider
Information: |
Bischofberger Norbert W |
| Relationship: |
Director |
| City: |
Foster City |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
3 |
|
| Direct
Shares |
2,846,606 |
|
|
Indirect Shares
|
7,743,294 |
|
|
| Direct
Value |
$1,252,176 |
|
|
|
Indirect Value
|
$148,061,064 |
|
|
| Total
Shares |
10,589,900 |
|
|
| Total
Value |
$149,313,240 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Gilead Sciences Inc |
GILD |
EVP, R&D and CSO |
2018-02-21 |
19,602 |
2018-02-21 |
2,317,800 |
Premium* |
|
|
Kronos Bio, Inc. |
KRON |
|
2024-02-15 |
2,811,004 |
2024-02-15 |
5,425,494 |
Premium* |
|
|
Vir Biotechnology, Inc. |
VIR |
Director |
2024-05-29 |
16,000 |
2024-05-29 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
193 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 7 of 8
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| GILD |
Gilead Sciences Inc |
EVP, Research |
• – – |
2005-08-17 |
4 |
OE |
$7.30 |
$913,832 |
D/D |
123,704 |
601,573 |
|
- |
|
| GILD |
Gilead Sciences Inc |
EVP, R&D and CSO |
• – – |
2015-02-17 |
4 |
A |
$0.00 |
$0 |
D/D |
129,108 |
248,658 |
0 |
- |
|
| GILD |
Gilead Sciences Inc |
EVP, Research |
• – – |
2007-02-09 |
4 |
S |
$71.20 |
$9,540,214 |
D/D |
(133,920) |
525,381 |
0 |
- |
|
| GILD |
Gilead Sciences Inc |
EVP, Research |
• – – |
2006-02-14 |
4 |
OE |
$7.40 |
$1,371,366 |
D/D |
136,488 |
655,069 |
|
- |
|
| GILD |
Gilead Sciences Inc |
EVP, Research |
• – – |
2006-02-14 |
4 |
S |
$59.02 |
$8,064,332 |
D/D |
(136,488) |
518,581 |
|
- |
|
| GILD |
Gilead Sciences Inc |
EVP, Research |
• – – |
2006-10-25 |
4 |
OE |
$17.89 |
$2,503,900 |
D/D |
140,000 |
659,301 |
0 |
- |
|
| GILD |
Gilead Sciences Inc |
EVP, Research |
• – – |
2007-02-09 |
4 |
OE |
$16.44 |
$2,301,250 |
D/D |
140,000 |
659,301 |
0 |
- |
|
| GILD |
Gilead Sciences Inc |
EVP, R&D and CSO |
• – – |
2009-07-24 |
4 |
OE |
$16.01 |
$2,241,400 |
D/D |
140,000 |
1,230,604 |
0 |
- |
|
| GILD |
Gilead Sciences Inc |
EVP, R&D and CSO |
• – – |
2008-04-30 |
4 |
OE |
$15.27 |
$2,289,750 |
D/D |
150,000 |
1,225,733 |
0 |
- |
|
| GILD |
Gilead Sciences Inc |
EVP, R&D and CSO |
• – – |
2008-07-24 |
4 |
S |
$52.07 |
$7,810,530 |
D/D |
(150,000) |
1,076,525 |
0 |
- |
|
| GILD |
Gilead Sciences Inc |
EVP, R&D and CSO |
• – – |
2008-07-24 |
4 |
OE |
$15.27 |
$2,289,750 |
D/D |
150,000 |
1,226,525 |
0 |
- |
|
| GILD |
Gilead Sciences Inc |
EVP, R&D and CSO |
• – – |
2008-11-07 |
4 |
S |
$45.10 |
$6,765,330 |
D/D |
(150,000) |
1,076,525 |
0 |
- |
|
| GILD |
Gilead Sciences Inc |
EVP, R&D and CSO |
• – – |
2008-11-07 |
4 |
OE |
$15.27 |
$2,289,750 |
D/D |
150,000 |
1,226,525 |
0 |
- |
|
| GILD |
Gilead Sciences Inc |
EVP, R&D and CSO |
• – – |
2008-02-08 |
4 |
S |
$44.40 |
$7,063,189 |
D/D |
(158,820) |
1,062,733 |
0 |
- |
|
| GILD |
Gilead Sciences Inc |
EVP, Research |
• – – |
2005-02-15 |
4 |
S |
$33.10 |
$5,513,043 |
D/D |
(166,296) |
448,182 |
|
- |
|
| GILD |
Gilead Sciences Inc |
EVP, Research |
• – – |
2005-02-15 |
4 |
OE |
$7.30 |
$1,213,445 |
D/D |
166,296 |
614,478 |
|
- |
|
| GILD |
Gilead Sciences Inc |
EVP, R&D and CSO |
• – – |
2008-02-08 |
4 |
OE |
$8.94 |
$2,089,250 |
D/D |
170,000 |
1,221,553 |
0 |
- |
|
| GILD |
Gilead Sciences Inc |
EVP, R&D and CSO |
• – – |
2009-02-04 |
4 |
S |
$52.43 |
$9,096,634 |
D/D |
(173,452) |
1,076,525 |
0 |
- |
|
| GILD |
Gilead Sciences Inc |
EVP, R&D and CSO |
• – – |
2009-02-04 |
4 |
OE |
$15.27 |
$2,662,645 |
D/D |
173,452 |
1,249,977 |
0 |
- |
|
| GILD |
Gilead Sciences Inc |
SVP, Research |
• – – |
2004-10-28 |
4 |
OE |
$7.30 |
$1,313,442 |
D/D |
180,000 |
595,550 |
|
- |
|
| GILD |
Gilead Sciences Inc |
SVP, Research |
• – – |
2004-10-28 |
4 |
S |
$35.00 |
$6,335,590 |
D/D |
(180,000) |
415,550 |
|
- |
|
| GILD |
Gilead Sciences Inc |
EVP, R&D and CSO |
• – – |
2009-07-24 |
4 |
S |
$48.00 |
$8,661,324 |
D/D |
(180,448) |
1,050,156 |
0 |
- |
|
| GILD |
Gilead Sciences Inc |
EVP, Research |
• – – |
2005-05-06 |
4 |
S |
$38.40 |
$7,166,914 |
D/D |
(186,504) |
477,150 |
|
- |
|
| GILD |
Gilead Sciences Inc |
EVP, Research |
• – – |
2005-05-06 |
4 |
OE |
$7.41 |
$1,381,305 |
D/D |
186,504 |
634,686 |
|
- |
|
| KRON |
Kronos Bio, Inc. |
President & CEO |
• • – |
2020-12-10 |
4 |
A |
$0.00 |
$0 |
D/D |
198,124 |
198,124 |
0 |
- |
|
193 Records found
|
|
Page 7 of 8 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
